Media, investigators, organizations issuing press releases, and others with access to research accepted for presentation during THT 2026 are required to abide by the embargo policies governing CRF^® meetings.

The Cardiovascular Research Foundation^® embargoes information presented as a late-breaking clinical trial, late-breaking clinical science, or featured clinical research. Coverage of these studies is strictly prohibited until the start time of each trial’s official presentation as listed in the THT 2026 Program on the official THT website. No journalist, exhibitor, or university (or affiliated organization or company) may disseminate information until the trial’s official presentation time. All embargo times are listed in Eastern Standard Time (EST). There is no official embargo for research presented as an abstract, challenging case, or during an innovation session. However, to maximize the impact of your presentation we recommend that no data be shared until the start of THT 2026 and ideally not before your formal presentation.

For questions regarding the embargo policy, please email [email protected].

Press releases announcing activities and/or research at THT 2026 must adhere to the following guidelines:

• All news releases must comply with CRF^®’s embargo policy.
• Releases must include a reference to THT 2026 in the body, preferably in the first paragraph. Suggested language is provided below.
  • Suggested language: “… presented at THT 2026, the annual conference organized by the Cardiovascular Research Foundation^® (CRF^®)”
• A copy of the press release, or draft press release, must be submitted in advance for review and approval. Please email the press release to the contact below. All submissions will be treated with strict confidentiality.
• Releases must not imply that CRF^® endorses any product or service.
• Releases must not be scientifically misleading or ethically questionable.